The autoimmune origin of atherosclerosis

Atherosclerosis

Volumn 201, Issue 1, 2008, Pages 17-32

  Blasi, Claudio ^a  

^a ASL Roma B   (Italy)

Author keywords

Atherosclerosis; Autoimmunity; Chlamydia pneumoniae; HSP; Immunotolerance; Oxidized LDL; T regulatory cells

Indexed keywords

AUTOANTIGEN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; IMMUNOMODULATING AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADAPTIVE IMMUNITY; AIR POLLUTION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; CELLULAR STRESS RESPONSE; CHRONIC INFLAMMATION; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; INFECTION; INNATE IMMUNITY; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SMOKING;

ATHEROSCLEROSIS; AUTOANTIGENS; AUTOIMMUNITY; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOMODULATION; LIPOPROTEINS, LDL; OXIDATIVE STRESS; RISK FACTORS; TUNICA INTIMA;

EID: 53849105417     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.05.025     Document Type: Review

References (248)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
2. Ludewig B., Zinkernagel R.M., and Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc Med 12 (2002) 154-159
3. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
4. Kalayoglu M.V. Chlamydial heat shock protein 60 and lypopolisaccharide: potential virulence determinants in atherogenesis. Curr Drugs Tar Infl Aller 1 (2002) 249-255
5. Sigal L.H. Basic science for the clinician 44. Atherosclerosis: an immunologically mediated (autoimmune?) disease. J Clin Rheumatol 13 (2007) 160-168
6. Sherer Y., and Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2 (2006) 99-106
7. Rose N., and Afanasyeva M. Autoimmunity: busting the atherosclerotic plaque. Nat Med 9 (2003) 641-642
8. Binder C.J., Shaw P.X., Chang M.-K., et al. The role of natural antibodies in atherogenesis. J Lipid Res 46 (2005) 1353S-1363S
9. Gordon P.A., George J., Khamashta M.A., et al. Atherosclerosis and autoimmunity. Lupus 10 (2001) 249-252
10. Pershinka H., Wellenzohn B., Parson W., et al. Identification of atherosclerosis-associated conformational heat shock protein 60 epitopes by phage display and structural alignment. Atherosclerosis 194 (2007) 79-87
11. Doherty T.M., Fisher E.A., and Arditi M. TLR signalling and trapped vascular dendritic cells in the development of atherosclerosis. Trends Immunol 27 (2006) 222-227
12. Prohászka Z., and Füst G. Immunological aspects of heat-shock proteins-the optimum stress of life. Mol Immunol 41 (2004) 29-44
13. Xiao Q., Mandal K., Schett G., et al. Association of serum-soluble heat shock protein 60 with carotid atherosclerosis. Stroke 36 (2005) 2571-2576
14. Mandal K., Jahangiri M., and Xu Q. Autoimmunity to heat shock proteins in atherosclerosis. Autoimm Rev 3 (2004) 31-33
15. Hansson G.K., and Libby P. The immune response in atherosclerosis: a double edged sword. Nat Rev Immunol 6 (2006) 508-518
16. Groyer E., Caligiuri G., Laschet-Khallou J., and Nicoletti A. Immunologic aspects of atheroma. Presse Med 35 (2006) 475-486
17. Mouthon L. L'athérosclérose est-elle une maladie immunologique?. Presse Med 35 (2006) 454-455
18. Binder C.J., Hartvigsen K., and Witztum J.L. Promise of immune modulation to inhibit atherogenesis. J Am Coll Cardiol 50 (2007) 547-550
19. Buttari B., Profumo E., Petrone L., et al. Free hemoglobin. A dangerous signal for the immune system in patients with carotid atherosclerosis?. Ann NY Acad Sci 1107 (2007) 42-50
20. Benagiano M., D'Elios M.M., Amedei A., et al. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerostic plaques. J Immunol 174 (2005) 6509-6517
21. Browning J.L. B cells move to the centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5 (2006) 564-575
22. Mackay I.R., Leskovsek N., and Rose N.R. Cell damage and autoimmunity: a critical appraisal. J Autoimm 30 (2008) 5-11
23. Pisetsky D.S. Fulfilling Koch's postulates of autoimmunity: anti-NR2 antibodies in mice and men. Arthr Rheum 54 (2006) 2349-2352
24. Davidson A., and Diamond B. Autoimmune diseases. N Engl J Med (2001) 345-350
25. Marrack P., Kappler J., and Kotzin B.L. Autoimmune disease: why and where it occurs. Nat Med 7 (2001) 899-905
26. Rose N.R., and Bona C. Defining criteria for autoimmune diseases (Witebsky' postulates revisited). Immunol Today 14 (1993) 426-430
27. Greco T.P., Conti-Kelly A.M., Matsuura E., et al. Antiphospholipid antibodies in patients with coronary artery disease. Ann NY Acad Sci 1108 (2007) 466-474
28. Wen L., and Wong F.S. How can the innate immune system influence autoimmunity in type 1 diabetes and other autoimmune disorders?. Crit Rev Immunol 25 (2005) 225-250
29. Zhou X., Nicoletti A., Elhage R., et al. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102 (2000) 2919-2922
30. Robertson A.K.L., and Hansson G.K. T cells in atherogenesis. For better or for worse?. Arterioscler Thromb Vasc Biol 26 (2006) 2421-2432
31. Mehta T.A., Greenman J., Ettelaie C., et al. Heat shock proteins in vascular diseases-a review. Eur J Varsc Endovasc Surg 29 (2005) 395-402
32. Wick G., Knoflach M., and Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22 (2004) 361-403
33. Xu Q., Kleindienst R., Waitz W., et al. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J Clin Invest 91 (1993) 2693-2702
34. Xu Q., Dietrich H., Steiner H.J., et al. Induction of atherosclerosis in normocholesterolaemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 12 (1992) 789-799
35. George J., Shoenfeld Y., Afek A., et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 19 (1999) 505-510
36. Shoenfeld Y., Gerli R., Doria A., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112 (2005) 3337-3347
37. Abou-Raya A., and Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimm Rev 5 (2006) 331-337
38. Pertovaara M., Raitala A., Juonala M., et al. Autoimmunity and atherosclerosis: functional polymorphism of PTPN22 is associated with phenotypes related to the risks of atherosclerosis. The Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 147 (2007) 265-269
39. Michelsen K.S., Doherty T.M., Shah P.K., and Arditi M. TLR (signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 173 (2004) 5901-5907
40. Widlansky M.E., Gokce N., Keaney J.F., and Vita J.A. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42 (2003) 1149-1160
41. Perschinka H., Mayr M., Millonig G., et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 1060-1065
42. Spitaler M.M., and Graier W.F. Vascular targets of redox signaling in diabetes mellitus. Diabetologia 45 (2002) 476-494
43. Madamanchi N.R., and Runge M.S. Mitochondrial dysfunction and atherosclerosis. Circ Res 100 (2007) 460-473
44. Taylor R.P., and Benjamin I.J. Small heat shock proteins: a new classification scheme in mammals. J Mol Cell Cardiol 38 (2005) 433-444
45. Freeman B.A., and Crapo J.D. Biology of disease: free radicals and tissue injury. Lab Invest 47 (1982) 412-426
46. Gleimer M., and Parham P. Stress management: MHC class I and class I-like molecules as reporters of cellular stress. Immunity 19 (2003) 469-477
47. Hirono S., Dibrov E., Hurtado C., et al. Chlamydia pneumoniae stimulates proliferation of vascular smooth muscle cells through induction of endogenous heat shock protein 60. Circ Res 93 (2003) 710-716
48. Asea A. Chaperokine-induced signal transduction pathways. Exerc Immunol Rev 9 (2003) 25-33
49. Winter J., and Jakob U. Beyond transcription-new mechanisms for regulation of molecular chaperones. Crit Rev Biochem Mol Biol 39 (2004) 297-317
50. Calderwood S.K. Regulatory interfaces between the stress protein response and other gene expression programs in the cell. Methods 35 (2005) 139-148
51. Voellmy R. The stress protein response: consequences of stress exposure - cytoprotection - potential diagnostic and therapeutic applications. Methods 35 (2005) 115-116
52. Hooper P.L., and Hooper J.J. Loss of defense against stress: diabetes and heat shock proteins. Diab Technol Therap 7 (2005) 204-208
53. Cornelussen R.N.M., Vanagt W.Y.R., Prinzen F.W., and Snoeckx L.H.E.H. Proteins involvement in salvage of the myocardium. In: Roach R.C., et al. (Ed). Hypoxia: through the lifecycle (2003), Kluver Academic/Plenum Publishers 1-15
54. Ritossa F. Discovery of heat shock response. Cell Stress Chaperones 1 (1996) 97-98
55. Marian A., and Nambi V. Biomarkers of cardiac disease. Expert Rev Mol Diagn 4 (2004) 1-11
56. van Eden W., van der Zee R., and Prakken B. Heat shock proteins induce T-cell regulation of chronic inflammation. Nat Rev 5 (2005) 318-330
57. Metzler B., Abia R., Ahmad M., et al. Activation of heat shock transcription factor 1 in atherosclerosis. A. J Pathol 162 (2003) 1669-1676
58. Pfister G., Stroh C.M., Perchinka H., et al. Detection of HSP60 on the membrane surface of stressed human endothelial cells by atomic force and cofocal microscopy. J Cell Sci 118 (2005) 1587-1594
59. Armitage J.D., Homer-Vanniasinkam S., and Lindsey N.J. The role of endothelial cell reactive antibodies in peripheral vascular disease. Autoimm Rev 3 (2004) 39-44
60. van Eden W. Immunoregulation of autoimmune diseases. Hum Immunol 67 (2006) 446-453
61. Prakken B.J., Roord A., Ronaghy A., et al. Heat shock protein 60 and adjuvant arthritis: a model for Tregulation in human arthritis. Sprinter Semin Immunopathol 25 (2003) 47-63
62. Zhao R., and Shen G.X. Involvement of heat shock factor-1 in glycated LDL-induced upregulation of plasminogen activator inhibitor-1 in vascular endothelial cells. Diabetes 56 (2007) 1436-1444
63. Zhu J., Katz R.J., Quyyumi A.A., et al. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels. Suggestion of pathogen-triggered autoimmunity in early atherosclerosis. Circulation 109 (2004) 36-41
64. Sun E. Cell death recognition model for immune system. Med Hypoth 70 (2008) 585-596
65. Köhl J. The role of complement in danger sensing and transmission. Immunol Res 34 (2006) 157-176
66. Campisi J., Leem T.H., and Fleshner M. Stress-induced extracellular Hsp 72 is a functional significant danger signal to the immune system. Cell Stress Chaperones 8 (2003) 272-286
67. Lamb D.J., El-Sankary W., and Ferns G.A.A. Molecular mimicry in atherosclerosis: a role of heat shock proteins in immunization. Atherosclerosis 167 (2003) 177-185
68. Riganò R., Profumo E., Buttari B., et al. Heat shock proteins and autoimmunity in patients with carotid atherosclerosis. Ann NY Acad Sci 1107 (2007) 1-10
69. Alard J.-E., Dueymes M., Youinou P., and Jamin C. Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. Autoimm Rev 6 (2007) 438-443
70. Ghayour-Mobarhan M., Lamb D.J., Tavallaie S., and Ferns G.A. Relationship between plasma cholesterol, von Willebrand factor concentrations extent of atherosclerosis and antibody titres to heat shock protein -60, -65 and -70 in cholesterol-fed rabbits. J Exp Pathol 88 (2007) 249-251
71. Knoflach M., Kiechl S., Kind M., et al. Cardiovascular risk factors and atherosclerosis in young males. ARMY study. Circulation 108 (2003) 1064-1069
72. Zhu J., Quyyumi A.A., Rott D., et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103 (2001) 1071-1075
73. Xu Q., Schett G., Perschinka H., et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 102 (2000) 14-20
74. Rieger R., and Gershwin M.E. The x and why of xenobiotics in primary biliary cirrhosis. J Autoimm 28 (2007) 76-84
75. Fujinami R.S., von Herrath M.G., Christen U., and Whitton J.L. Molecular mimicry, bystander activation or viral persistence: infections and autoimmune disease. Clin Microb Rev 19 (2006) 80-94
76. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6 (2006) 823-835
77. Wick G., Henderson B., Knoflach M., et al. Atherosclerosis: autoimmunity to heat-shock proteins. In: Rose N.R., and Mackay I.R. (Eds). The autoimmune diseases. 4th ed. (2006), Academic Press 889-897
78. Zhou X., and Hansson G. Vaccination and atherosclerosis. Curr Atheroscl Rep 6 (2004) 158-164
79. Noguchi N. Novel insights into the molecular mechanisms of the antiatherosclerotic properties of antioxidants: the alternatives to radical scavenging. Free Radic Biol Med 33 (2002) 1480-1489
80. Zal B., Kaski J.C., Arno G., et al. Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation 109 (2004) 1230-1235
81. Hallenbeck J.M., Hansson G.K., and Becker K.J. Immunology of ischemic vascular disease: claque to attack. Trends Immunol 26 (2005) 550-555
82. Nilsson J., Hansson G., and Shah P.K. Immunomodulation of atherosclerosis. Implications for vaccine development. Arterioscler Thromb Vasc Biol 25 (2005) 18-28
83. Matsuura E., Kobayashi K., Tabuchi M., and Lopez L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Progr Lipid Res 45 (2006) 466-486
84. Yan Z-q, and Hansson G. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219 (2007) 187-203
85. Saad A.F., Virella G., Chassereau C., Boackle R.J., and Lopes-Virella M.F. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 47 (2006) 1975-1983
86. Shaw P.X., Hörkkö S., Tsimikas S., et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21 (2001) 1333-1339
87. Hansson G.K., Libby P., Schonbeck U., and Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91 (2002) 281-291
88. Lehtimäki T., Lehtinen S., Solakivi T., et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19 (1999) 23-27
89. Conrad K., Bachmann M.P., Matsuura E., and Shoenfeld Y. From animal models to human genetics: research on the induction and pathogenicity of autoantibodies. Autoimm Rev 4 (2005) 178-187
90. 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44 (2003) 716-726
91. Jara L.J., Medina G., Vera-Lasta O., et al. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimm Rev 5 (2006) 195-201
92. 2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann NY Acad Sci 1051 (2005) 97-103
93. Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25 (2005) 1776-1785
94. Kobayashi K. Atherogenic antiphospholipid antibodies in antiphospholipid syndrome. Ann NY Acad Sci 1108 (2007) 489-496
95. Fahdi I.E., Gaddam V., Garza L., Romeo F., and Mehta J.L. Inflammation, infection, and atherosclerosis. Brain Behav Immun 17 (2003) 238-244
96. Zhang G., and Ghosh S. Toll-like receptor-mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107 (2001) 13-19
97. Hansson G.K., and Paulsson Berne G. Atherosclerosis and the immune system. Acta Paediatr Suppl. 446 (2004) 63-69
98. Kiechl S., Wiedermann C.J., and Willeit J. Toll-like receptor 4 and atherogenesis. Ann Med 35 (2003) 164-171
99. Birk O.S., Gur S.L., Elias D., et al. The 60-kDa heat shock protein modulates allograft rejection. Proc Natl Acad Sci 96 (1999) 5159-5163
100. Kuiper J., van Puijvelde G.H., van Wanrooij E.J., et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol 18 (2007) 521-526
101. Cook D.N., Pisetsky D.S., and Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5 (2004) 975-979
102. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347 (2002) 185-192
103. Li H., and Sun B. Toll-like receptors in atherosclerosis. J Cell Mol Med 11 (2007) 88-95
104. Blasi C. The role of infectious agents in the pathogenesis and evolution of atherosclerosis. Ann Ital Med Int 19 (2004) 249-261
105. Kiechl S., Egger G., Mayr M., et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103 (2001) 1064-1070
106. Goyal P., Kale S.C., Chaudhry R., Chauhan S., and Shah N. Association of common chronic infections with coronary artery disease in patients without any conventional risk factors. Indian J Med Res 124 (2007) 129-136
107. Ayada K., Yokota K., Kobayashi K., et al. Chronic infections and atherosclerosis. Ann NY Acad Sci 1108 (2007) 594-602
108. Ford P.J., Yamazaki H., and Seymour G.J. Cardiovascular and oral disease interactions: what is the evidence?. Prim Dent Care 14 (2007) 59-66
109. Zügel U., and Kaufman S.H.E. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 12 (1999) 19-39
110. Biondi-Zoccai G.G.L., Abbate A., Liuzzo G., and Biasucci L.M. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41 (2003) 1071-1077
111. Wick G., Perschinka H., and Xu Q. Autoimmunity and atherosclerosis. Am Heart J 138 (1999) S444-S449
112. Xu Q., Kiechl S., Mayr M., et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 100 (1999) 1169-1174
113. Stille W., and Dittmann R. Atherosclerosis as a sequela of chronic Chlamydia pneumonia infection. Herz 23 (1998) 185-192
114. Bason C., Corrocher R., Lunardi C., et al. Interaction of antibodies against cytomegalovirus with heat shock protein 60 in pathogenesis of atherosclerosis. Lancet 362 (2003) 1971-1977
115. Choi E.Y., Dongsoo K., Hong B.K., et al. Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae: the potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis. Exp Mol Med 34 (2002) 391-400
116. Kol A., Sukhova G.K., Lichtman A.H., and Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 98 (1998) 300-307
117. Hammerschlag M.R. The intracellular life of chlamydiae. Semin Pediatr Infect Dis 13 (2002) 239-248
118. Beatty W., Morrison R.P., and Byrne G.I. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58 (1994) 686-699
119. Mayr M., Metzler B., Kiechl S., et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae. Circulation 99 (1999) 1560-1566
120. Kalayoglu M.V., Libby P., and Byrne G.I. Chlamydia Pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288 (2002) 2724-2731
121. Schett G., Xu Q., Amberger A., et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 96 (1995) 2569-2577
122. Shi Y., and Tokunaga O. Chlamydia pneumoniae and multiple infections in the aorta contribute to atherosclerosis. Pathol Int 52 (2002) 755-763
123. Xu Q., Schett G., Seitz C.S., et al. Surface staining and cytotoxic activity of heat-shock protein 60 antibody in stressed aortic endothelial cells. Circ Res 75 (1994) 1078-1085
124. Kol A., Bourcier T., Lichtman A.H., et al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103 (1999) 571-577
125. Kuroda S., Kobayashi T., Ishii N., et al. Role of Chlamidia pneumoniae-infected macrophages in atherosclerosis developments of carotid artery. Neuropathology 23 (2003) 1-8
126. Liuzzo G., Giubilato G., and Pinnelli M. T cells and cytokines in atherogenesis. Lupus 14 (2005) 732-735
127. Arcari C.M., Gaydos C., Nieto J., et al. Association between Chlamydia pnumoniae and acute myocardial infarction in young men in the Unites States military: the importance of timing of exposure measurement. Clin Infect Dis 40 (2005) 1123-1130
128. Kuo C.C., and Campbell L.A. Detection of Chlamydia pneumoniae in arterial tissue. J Infect Dis 181 (2000) S432-S436
129. Wong Y.K., Gallagher P.J., and Ward M.E. Chlamydia pneumoniae and atherosclerosis. Heart 81 (1999) 232-238
130. de Kruif M.D., van Gorp E.C.M., Keller T.T., et al. Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 65 (2005) 317-327
131. Cao F., Castrillo A., Tontonoz P., Re F., and Byrne G.I. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by toll-like receptor 2. Infect Immun 75 (2007) 753-759
132. Bobryshev Y.V., Lord R.S.A., and Tran D. Chlamydia pneumoniae in foci of "early" calcification of the tunica media in arteriosclerotic arteries: an incidental presence?. Am J Physiol Heart Circ Physiol 290 (2006) H1510-H1519
133. Foti M., Granucci F., Pelizzola M., et al. Dendritic cells in pathogen recognition and induction of immune responses: a functional genomics approach. J Leuk Biol 79 (2006) 913-916
134. Gao S.Z., Schröder J.S., Alderman E.L., et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation 80 (1989) 100-105
135. Valantine H.A. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 76 (2003) 891-899
136. Rahmani M., Cruz R.P., Granville D.J., and Mc Manus B.M. Allograft vasculopathy versus atherosclerosis. Circ Res 99 (2006) 801-805
137. Lay J.C., Tranfield E.M., Walker D.C., et al. Ultrastructural evidence of early endothelial damage in coronary arteries of rat cardiac allografts. J Heart Lung Transplant 22 (2003) 993-1004
138. Pinney S.P., and Mancini D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol 19 (2004) 170-176
139. Orosz Z., Csiszar A., Labinskyy N., et al. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD(P) H oxidase activation. Am J Physiol Heart Circ Physiol 292 (2007) H130-H139
140. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., et al. Systemic effects of smoking. Chest 131 (2007) 1557-1566
141. Berhard D., and Wang X.L. Smoking, oxidative stress and cardiovascular diseases-do anti-oxidative therapies fail?. Curr Med Chem 14 (2007) 1689-1699
142. Aicher A., Heeshen C., Mohaupt M., et al. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 107 (2003) 604-611
143. Bai Ni, Khazaei M., van Eeden S.F., and Laher I. The pharmacology of particulate matter air pollution-induced cardiovascular dysfunction. Pharmacol Therap 113 (2007) 16-29
144. Sun Q., Wang A., Jin X., et al. Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA 294 (2005) 3003-3010
145. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: pathogenetic and regulatory pathways. Physiol Rev 86 (2006) 515-581
146. Oki S., and Miyake S. Invariant natural killer T (iNKT) cells in asthma: a novel insight to the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases. Allergol Int 56 (2007) 7-14
147. Stephens L.A., Gray D., and Anderton S.M. CD4+ CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci USA 102 (2005) 17418-17423
148. Choileain N.N., and Redmond H.P. Regulatory T-cells and auto-immunity. J Surg Res 130 (2006) 124-135
149. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345-352
150. Mallat Z., Ait-Oufella H., and Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med 17 (2007) 113-118
151. + regulatory T cells and their therapeutic potential. Ann Rev Med 57 (2006) 381-402
152. Romagnani S. Introduction: characterization and functions of human T regulatory cells. Microbes Infect 7 (2005) 1015-1016
153. Bluestone J.A. Regulatory T-cell therapy: is it ready for the clinic?. Nat Rev Immunol 5 (2005) 343-349
154. Sakaguchi S. Regulatory T cells: key controllers of immunologic self tolerance. Cell 101 (2000) 455-458
155. Faria A.M.C., and Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Devel Immunol 13 (2006) 143-157
156. Marleau A.M., and Sarvetnick N. T cell homeostasis in tolerance and immunity. J Leukoc Biol 78 (2005) 575-584
157. Mallat Z., Ait-Oufella H., and Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidology 16 (2005) 518-524
158. Danke N.A., Koelle D.M., Yee C., et al. Autoreative T cells in healthy individuals. J Immunol 172 (2004) 5967-5972
159. van Eden W., Hauet-Broere F., Berlo S., et al. Stress proteins as inducers and targets of regulatory T cells in arthritis. Int Rev Immunol 24 (2005) 181-197
160. Lan R.Y., Ansari A.A., Lian Z.-X., and Gershwin E. Regulatory T-cells: development, function and role in autoimmunity. Autoimm Rev 4 (2005) 351-363
161. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12 (2006) 178-180
162. Mor A., Luboshits G., Planer D., et al. Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes. Eur Heart J 27 (2006) 2530-2537
163. Prohászka Z. Chaperones as part of immune networks. Adv Exp Med Biol 594 (2007) 159-166
164. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.-K.L., and Flavell R.A. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 24 (2006) 99-146
165. Mor A., Planer D., Luboshits G., et al. Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 893-900
166. Bobryshev Y.V. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 26 (2005) 1700-1704
167. Del Prete A., Locati M., Otero K., et al. Migration of dendritic cells across blood and lymphatic endothelial barriers. Thromb Haemost 95 (2006) 22-28
168. Heeneman S., Donners M.P.C.M., Bai L., and Daemen M.J.A.P. Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?. Export Rev Cardiovasc Ther 5 (2007) 345-364
169. Mauriello A., Sangiorgi G., Frantoni S., et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 45 (2005) 1585-1593
170. Erbel C., Sato K., Meyer F.B., et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol 102 (2007) 123-132
171. Methe H., Brunner S., and Wiegand D. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 45 (2005) 1939-1945
172. Steppich B.A., Moog P., Matissek C., et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 190 (2007) 443-451
173. Goronzy J.J., and Weyand C.M. Immunosoppression in atherosclerosis. Mobilizing the opposition within. Circulation 114 (2006) 1901-1904
174. Caligiuri G., and Nicoletti A. Lymphocytes responses in acute coronary syndromes: lack of regulation spawns deviant behaviour. Eur Heart J 27 (2006) 2485-2486
175. Yildiz A., and Gur M. CD4+CD25+ regulatory T-cells in acute coronary syndromes. Eur Heart J 28 (2007) 774-775
176. Han S.F., Liu P., Zhang W., et al. The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol 124 (2007) 90-97
177. Hauet-Broere F., Wieten L., Guichelar T., et al. Heat shock proteins induce T cell regulation of chronic inflammation. Ann Rheum Dis 65 suppl. 3 (2006) iii65-iii68
178. Dasgupta S., Navarrete A.-M., Bayry J., et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. PNAS 104 (2007) 8965-8970
179. Niess J.H., and Reinecker H.-C. Dendritic cells in the recognition of intestinal microbiota. Cell Microbiol 8 (2006) 558-564
180. Schuurhuis D.H., Fu N., Ossendorp F., and Melief C.J.M. Ins and outs of dendritic cells. Int Arch Allergy Immunol 140 (2006) 53-72
181. Björkbacka H. Multiple roles of toll-like receptor signalling in atherosclerosis. Curr Opin Lipidol 17 (2006) 527-533
182. Zhou X., Paulsson G., and Stemme S. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerostic apo E-knockout mice. J Clin Invest 101 (1998) 1717-1725
183. Belland R.J., Ouellette S.P., Gieffers J., and Byrne G.I. Chlamydia pneumoniae and atherosclerosis. Cell Microbiol 6 (2004) 117-127
184. Erkkilä L., Laitinen K., Haasio K., et al. Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection. Atherosclerosis (2004) 321-328
185. Quiñones M.J., Nicholas S.B., and Lyon C.J. Insulin resistance and the endothelium. Curr Diab Rep 5 (2005) 246-253
186. Cersosimo E., and DeFronzo R.A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 22 (2006) 423-436
187. Lopes-Virella M.F., and Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosc 8 (2003) S750-S768
188. Grant J.P. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin 21 Suppl. 1 (2005) S5-S12
189. Pickup J.C., and Mattock M.B. Activation of the innate immune system as predictor of cardiovascular mortality in Type 2 diabetes mellitus. Diabetic Med 20 (2003) 723-726
190. Kanter J.E., Johansson F., LeBoeuf R.V., and Bornfeldt K.E. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques?. Circ Res 100 (2007) 769-781
191. Schleicher E., and Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl. 106 (2007) S17-S26
192. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 54 (2005) 1-7
193. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 54 (2005) 1615-1625
194. Price C.L., and Knight S.C. Advanced glycation: a novel outlook on atherosclerosis. Curr Pharm Des 13 (2007) 3681-3687
195. Stentz F.B., and Kitabchi A.E. Activated T lymphocytes in type 2 diabetes: implications from in vitro studies. Curr Drug Targ 4 (2003) 493-503
196. Korshunov S.S., Skulachev V.P., and Starkov A.A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 416 (1997) 15-18
197. Pennathur Du X.L., Edelstein D., Dimmeler S., et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest (2001) 1341-1348
198. Sims T.J., Lenmark A., Mancl L.A., et al. Serum IgG to heat shock proteins and Porphyromonas gingivalis antigens in diabetic patients with periodontitis. J Cl Periodont 29 (2002) 551-562
199. Shamaei-Tousi A., Stephens J.W., Bin R., et al. Association between plasma levels of heat shock protein 60 and cardiovascular disease in patients with diabetes mellitus. Eur Heart J 27 (2006) 1565-1570
200. Ghayour-Mobarhan M., Lamb D.J., Vaidya N., et al. Heat shock protein antibody titres are reduced by statin therapy in dyslipidemic subjects: a pilot study. Angiology 56 (2005) 61-68
201. Figueredo A., Ibarra J.l., Rodriguez A., et al. Increased serum levels of IgA antibodies to hsp70 protein in patients with diabetes mellitus: their relationship with vascular complications. Clin Immunol Immunopathol 79 (1996) 252-255
202. Genco R.J. Current view of risk factors for periodontal diseases. J Periodontol 67 Suppl. 10 (1996) 1041-1049
203. Prasad A., Zhu J., Halcox J., et al. Predisposition to atherosclerosis by infections. Circulation 106 (2002) 184-190
204. Maiti R., and Agrawal N.K. Atherosclerosis in diabetes mellitus: role of inflammation. Indian J Med Sci 61 (2007) 292-306
205. Moutschen M.P., Scheen A.J., and Lefebvre P.J. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 18 (1992) 187-201
206. Grant-Theule D.A. Periodontal disease, diabetes, and immune response: a review of current concepts. J West Soc Periodontol Periodontal Abstr 44 (1996) 69-77
207. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
208. Calkin A.C., and Allen T.J. Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention. Am J Cardiovasc Drugs 6 (2006) 15-40
209. Wraith D.C., McDevitt H.O., Steinman L., and Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. Cell 57 (1989) 709-715
210. Shovman O., Zandman-Goddard G., Sherer Y., et al. Immune tolerance as a strategy for treatment of atherosclerosis. Drug Disc Today 2 (2005) 207-211
211. van Puijvelde G.H., Hauer A.D., de Vos P., et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114 (2006) 1968-1976
212. Harats D., Yacov N., Gilburd B., et al. Oral tolerance with heat shock protein 65 attenuates Mycobcterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 40 (2002) 1333-1338
213. van Puijvelde G.H., van Es T., van Wanrooij E.J., et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterios Thromb Vasc Biol 27 (2007) 2677-2683
214. van Eden W., Wick G., Albani S., and Cohen I. Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are able to be used for the control of chronic inflammatory diseases. Ann NY Acad Sci 1113 (2007) 217-237
215. Shah P.K., Chyu K.Y., Fredrikson G.N., and Nilsson J. Vaccination for atherosclerosis: a novel therapeutic paradigm. Expert Rev Vaccines 3 (2004) 711-716
216. Khallou-Lashet J., Tupin E., Caligiuri G., et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 184 (2006) 330-341
217. Mc Devitt H. Specific antigen vaccination to treat autoimmune disease. PNAS 101 Suppl. 2 (2004) 14627-14630
218. Shah P.K., Chyu K.-Y., Fredrikson G.N., et al. Immunomodulation of atherosclerosis with a vaccine. Nat Clin Pract Cardiov Med 2 (2005) 639-646
219. Fredrikson G.N., Söderberg I., Lindholm M., et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100peptide sequences. Arterioscl Thromb Vasc Biol 23 (2003) 879-884
220. Fredrikson G.N., Schiopu A., Berglund G., et al. Autoantibodies against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 194 (2007) e188-e192
221. Caligiuri G., Khallou-Lashet J., Vandaele M., et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50 (2007) 540-546
222. Schiopu A., Bengtsson J., Söderberg I., et al. Recombinant human antibodies against aldehyde modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 110 (2004) 2047-2052
223. Kobayashi K., Lopez L.R., Shoenfeld Y., and Matsuura E. The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann NY Acad Sci 1051 (2005) 442-454
224. Toubi E., and Shoenfeld Y. Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?. Lupus 14 (2005) 665-669
225. Ström A., FredriksonGN, Schiopu A., et al. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis 190 (2007) 298-305
226. Schiopu A., Frendéus B., Jansson B., et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-)mice. J Am Coll Cardiol 50 (2007) 2313-2318
227. Zhou X., Robertson A.K., Rudling M., et al. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 96 (2005) 395-397
228. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116 (2005) 949-959
229. Steffens S., Burger F., Pelli G., et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 114 (2006) 1977-1984
230. Penna G., Giarratana N., Amuchastegui S., et al. Manipulating dendritic cells to induce regulatory T cells. Microbes Infect 7 (2005) 1033-1039
231. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 233 (2005) 115-124
232. van Etten E., Decallonne B., Verlinden L., et al. Analogs of 1α, 25-dihydroxyvitamin D3 as pluripotent immunomodulators. J Cell Biochem 88 (2003) 223-226
233. Ehrenstein M.R., Evans J.G., Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF therapy. J Exp Med 200 (2004) 277-285
234. + regulatory T-cell function in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today 11 (2006) 952-956
235. Valencia X., Stephens G., Goldbach-Mansky R., et al. TNF downmodulates the function of human CD4+CD25high T-regulatory cells. Blood 108 (2006) 253-261
236. Chang J., and Girgis L. Clinical use of anti-TNF-α biological agents. A guide for GPs. Aust Fam Phys 36 (2007) 1035-1039
237. Williams Jr. R.C. Autoimmune disease aetiology-a perplexing paradox or a turning leaf?. Autoimm Rev 6 (2007) 204-208
238. Kuek A., Hazleman B.L., and O{combining double acute accent}stör A. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 83 (2007) 251-260
239. Marrack P. Conference summary. Proc Am Thorac Soc, vol. 4 (2007) 469-471
240. Yang K., Li D., Luo M., and Hu Y. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis. Cell Immunol 243 (2006) 90-95
241. Thornton A.M., and Shevach E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164 (2000) 183-190
242. Greenwood J., Steinman L., and Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6 (2006) 358-370
243. Dunn S.E., Youssef S., Goldstein M.J., et al. Isoprenoids determine Th1/Th2 fate in pathogenetic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 54 (2006) 1-13
244. Yilmaz A., Reiss C., Tantawi O., et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172 (2004) 85-93
245. + T cells. Atherosclerosis 197 (2008) 829-839
246. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
247. Brasier A.R., Recinos III A., and Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscl Thromb Vasc Biol 22 (2002) 1257-1266
248. Cipollone F., Fazia M., Iezzi A., et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109 (2004) 1482-1488